Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 2827 • 2014 ACR/ARHP Annual Meeting
Cervical Spine Fracture and Mortality in Ankylosing Spondylitis
Katherine D. Wysham¹, Sara G. Murray², Nancy K. Hills³, Edward H. Yelin⁴ and Lianne S. Gensler⁵, ¹Internal Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁴Arthritis Research Group, University of California, San Francisco, San Francisco, CA, ⁵Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Little data exist regarding mortality in Ankylosing Spondylitis (AS) patients. We performed a population-based study of diagnoses associated with hospital mortality in AS. Methods:…
Abstract Number: 2585 • 2014 ACR/ARHP Annual Meeting
Association of Smoking with Acute Phase Reactants and Molecules Involved in Bone Formation in Patients with Ankylosing Spondylitis
Grigorios Sakellariou¹, Spyros Gerou², Dimitrios Oikonomou³ and Fares Sayegh⁴, ¹Rheumatology, 424 General Military Hospital, Thessaloniki, Greece, ²Laboratories "Analysis", Thessaloniki, Greece, ³Biopathology, 424 General Military Hospital, Thessaloniki, Greece, ⁴3rd Orthopaedic, "Papageorgiou" General Hospital, Thessaloniki, Greece
Background/Purpose: In patients with ankylosing spondylitis (AS), smoking is associated with increased disease activity and more radiographic damage. However, the mechanisms underlying the effects of…
Abstract Number: 1596 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcome of Golimumab Treatment Differs Between Bio-naïve and Patients Previously Exposed to Biologicals. Nationwide Results on Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and Other Spondylarthritidies (SpA)
Saedis Saevarsdottir¹, Michele Santacatterina², Carl Turesson³, Helena Forsblad⁴, Lennart Jacobsson⁴ and Staffan Lindblad⁵, ¹Rheumatology Unit, Department of Medicine, Karolinska institutet and Karolinska University Hospital, Stockholm, Sweden, ²Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁵Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
Background/Purpose Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of RA, PsA and AS. Our previous…
Abstract Number: 596 • 2014 ACR/ARHP Annual Meeting
Clinical Value of ASDAS Index in Spanish Patients with Ankylosing Spondylitis
Agusti Sellas-Fernandez¹, Jose Luis Guerra Vázquez², Jose Luis Casals³, Carlos Gonzalez Fernandez⁴, Roberto Miguelez⁵, José Rosas⁶, Antonio Fernandez-Nebro⁷, Cilia Peralta Ginés⁸, Carlos Montilla-Morales⁹, Xavier Juanola¹⁰, Miguel Ángel Abad¹¹, Alberto Alonso¹², Azucena Hernández-Sanz¹³, Luis Francisco Linares¹⁴, Julio Medina¹⁵, Joana Rovira¹⁶, Juan Carlos Torre-Alonso¹⁷, Alfredo Willisch¹⁸, Eduardo Collantes-Estevez¹⁹ and Ana Ruiz-Zorrilla²⁰, ¹H. Vall d'Hebron, Barcelona, Spain, ²H. Arquitecto Marcide, La Coruña, Spain, ³H. Virgen de la Victoria, Málaga, Spain, ⁴Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵H. de Móstoles, Madrid, Spain, ⁶Rheumatology, Hospital Marina Baixa, Villajoyosa, Valencia, Alicante, Spain, ⁷Rheumatology, Hospital Regional Universitario Carlos Haya, Málaga, Spain, ⁸H. Clínico Lozano Blesa, Zaragoza, Spain, ⁹H. de Salamanca, Salamanca, Spain, ¹⁰Rheumatology, University Hospital Bellvitge, Barcelona, Spain, ¹¹Hospital Virgen del Puerto, Cáceres, Spain, ¹²Hospital de Cruces, Bilbao, Spain, ¹³H. Virgen de la Salud, Toledo, Spain, ¹⁴Hospital Virgen de la Arrixaca., Murcia, Spain, ¹⁵Hospital Clínico, Valladolid, Spain, ¹⁶Mutua Terrasa, Barcelona, Spain, ¹⁷Rheumatology Department, H. Monte Naranco, Oviedo, Spain, ¹⁸Complexo Hospitalario de Ourense, Ourense, Spain, ¹⁹Hospital Reina Sofía, Córdoba, Spain, ²⁰Abbvie, Madrid, Spain
Background/Purpose The ASDAS (ankylosing spondylitis disease activity score) was developed to overcome some of the deficiencies of BASDAI (Bath Ankylosing Disease Activity Spondyltis Index). In…
Abstract Number: 544 • 2014 ACR/ARHP Annual Meeting
Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis
James T. Rosenbaum^1,2, Martin Rudwaleit³, Robert B. M. Landewé⁴, Helena Marzo-Ortega^5,6, Joachim Sieper⁷, Désirée M. van der Heijde⁸, Owen Davies⁹, Christian Stach¹⁰, Tommi Nurminen¹⁰ and Atul A. Deodhar¹¹, ¹OHSU, Portland, OR, ²Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ³Endokrinologikum, Berlin, Germany, ⁴Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁵Leeds Teaching Hospitals NHS Trust and NIHR Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁶University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁷Rheumatology Department,, University Hospital Charité, Berlin, Germany, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Monheim, Germany, ¹¹Oregon Health and Sciences University, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) is characterized by inflammation in the spine and sacroiliac joints, but can also manifest as inflammation at extra-spinal sites, most commonly…
Abstract Number: 2829 • 2014 ACR/ARHP Annual Meeting
Spondyloarthritis Is Associated with Increased Cardiovascular and Cerebrovascular Mortality
Nigil Haroon¹, Nisha Nigil Haroon², Ping Li³, Michael Paterson³ and Robert D. Inman⁴, ¹Toronto Western Research Institute, Toronto, ON, Canada, ²Medicine, University of Toronto, Toronto, ON, Canada, ³Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, ⁴Immunlogy and Institute of Medical Science, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose OnSpA is a population-based study of spondyloarthritis (SpA) based on a provincial population of over 13 million. Patients with SpA are thought to be…
Abstract Number: 2571 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Risk of Cardiovascular Disease in Patients with Ankylosing Spondylitis with High and Low Body Mass Index
Inger Jorid Berg¹, Anne Grete Semb², Désirée van der Heijde^3,4, Tore K. Kvien⁴, Hanne Dagfinrud⁴, Jonny Hisdal^5,6 and Sella A. Provan², ¹Dep of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Section of Vascular Investigations, Oslo University Hospital Aker, Oslo, Norway, ⁶Faculty of Medicine, University of Oslo, Oslo, Norway
Background/Purpose Patients with ankylosing spondylitis (AS) have increased risk of cardiovascular disease (CVD), but the mediators of this increased risk are not known. Obesity is…
Abstract Number: 1540 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns of Biologics Used in Rheumatoid Arthritis and Ankylosing Spondylitis in the US Veterans Population
Brian Sauer¹, Chia-Chen Teng¹, Tao He¹, Jianwei Leng², Chao-Chin Lu¹, Neel Shah³, David J. Harrison⁴, Derek Tang⁴ and Grant W. Cannon⁵, ¹Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Salt Lake City VA and University of Utah, Salt Lake Citty, UT, ³1 Amgen Center Dr, Amgen Inc., Thousand Oaks, CA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Biologics used for rheumatoid arthritis (RA) and ankylosing spondylitis (AS), including tumor necrosis factor blockers, are a key area of focus for Veterans Affairs…
Abstract Number: 595 • 2014 ACR/ARHP Annual Meeting
Radiographic Sacroiliitis Progression in an Early Axial Spondyloarthritis Cohort
Concepcion Castillo-Gallego¹, Jesus Sanz², Carmen Martin-Hervas³, Mireia Moreno⁴, Victoria Navarro-Compán⁵, Diana Peiteado¹, Jorge Gratacos-Masmitja⁶, Eugenio De Miguel⁷ and Emilio Martín-Mola¹, ¹Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²Rheumatology, Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ³Radiology, Hospital Universitario La Paz, Madrid, Spain, ⁴Rheumatology, University Hospital Parc Taulí, Sabadell, Spain, ⁵Rheumatology, Rheumatologist, Madrid, Spain, ⁶Parc Tauli, S/N, Hospital Parc Tauli, Sabadell, Spain, ⁷Department of Rheumatology, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: The current concept of axial Spondyloarhtritis (axSpA) considers non-radiographic axSpA (nr-axSpA) and Ankylosing Spondylitis (AS) as two stages of one disease. There are limited…
Abstract Number: 543 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Désirée M. van der Heijde¹, Atul A. Deodhar², Owen Davies³, Tommi Nurminen⁴ and Martin Rudwaleit⁵, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim, Germany, ⁵Endokrinologikum, Berlin, Germany
Background/Purpose: Early response to anti-TNF therapy has been shown to be a strong predictor of good long-term outcomes in ankylosing spondylitis (AS).1 However, early identification…
Abstract Number: 2830 • 2014 ACR/ARHP Annual Meeting
Progression to and Type of Orthopaedic Surgery in Juvenile Vs. Adult-Onset Ankylosing Spondylitis
Deepak R. Jadon¹, Gavin Shaddick², Amelia Jobling³, Athimalaipet V Ramanan⁴ and Raj Sengupta¹, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Mathematics, University of Bath, Bath, United Kingdom, ³Department of Mathematical Sciences, University of Bath, Bath, United Kingdom, ⁴Paediatric Rheumatology, University of Bristol Hospital Trust, Bristol, United Kingdom
Background/Purpose: Juvenile-onset ankylosing spondylitis (JoAS) and adult-onset ankylosing spondylitis (AoAS) are subtypes of ankylosing spondylitis (AS) that may have different clinical outcome. We compared cohorts…
Abstract Number: 2567 • 2014 ACR/ARHP Annual Meeting
Vascular Endothelial Growth Factor and C-Reactive Protein Serum Levels Lack Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with the Tumor Necrosis Factor-Inhibitor Golimumab
Xenofon Baraliakos¹, Kay-Geert A. Hermann², Stephen Xu³, Benjamin Hsu³ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ³Janssen Research & Development, LLC., Spring House, PA
Background/Purpose Using data from GO-RAISE, we analyzed correlations between serum vascular endothelial growth factor (VEGF) and C-reactive protein (CRP) levels, radiographic progression and inflammation as…
Abstract Number: 1519 • 2014 ACR/ARHP Annual Meeting
Implementation of an Acid Dissociation Procedure for Immunogenicity Detection in Patients Treated with ANTI-TNF Drugs
Francisca Llinares-Tello¹, Jose Rosas², José M. Senabre-Gallego³, Gregorio Santos-Soler³, Carlos Santos-Ramirez⁴, Esteban Salas-Heredia³, Xavier Barber⁵, Juan Molina¹, Catalina Cano³, Ana Pons³ and Group Aire-MB³, ¹Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, ²Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, ³Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ⁴Rheumatology, Hospital Marina Salud, Denia, Spain, ⁵Universidad Miguel Hernández, CIO, Elche, Spain
Background/Purpose To evaluate the application of an acid dissociation procedure in monitoring patients with subtherapeutic serum concentrations of infliximab (IFX), adalimumab (ADL) and etanercept (ETN),…
Abstract Number: 593 • 2014 ACR/ARHP Annual Meeting
The Clinimetric Outcomes of Two Bath Ankylosing Spondyltis Metrology Indices in Treatment with TNF-á Blockers
Eon Jeong Nam¹, Jeong Soo Eun², Sang Hoon Kwon³ and Young Mo Kang⁴, ¹Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, South Korea, ²Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ³Internal medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ⁴Dept of Internal Medicine, Kyungpook National Univ Hosp, Daegu, South Korea
Background/Purpose Bath Ankylosing Spondyltis Metrology Index (BASMI) was developed to quantify the accurate axial status and to assess the clinical changes in spinal movement. The…
Abstract Number: 538 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Physical Function and Quality of Life in Subjects with Active Ankylosing Spondylitis: Results of a Phase 3 Randomized, Placebo-Controlled Trial with Intravenous Loading and Subcutaneous Maintenance Dosing
Atul A. Deodhar¹, Dominique L. Baeten², Jürgen Braun³, Xenofon Baraliakos³, Joachim Sieper⁴, Maxime Dougados⁵, Paul Emery⁶, Brian Porter⁷, Ruvie Martin⁷, Shephard Mpofu⁸ and Hanno Richards⁹, ¹Oregon Health and Sciences University, Portland, OR, ²Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Descartes University, Cochin Hospital, Paris, France, ⁶University of Leeds, Leeds, United Kingdom, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ankylosing spondylitis (AS) can have a profound negative effect on an individual's physical functioning, health status and quality of life (QoL), affecting the ability…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].